Biocon Biologics Biocon Campus (Site 1) facility gets 4 USFDA observations
Bangalore: Biocon has recently announced that the U.S. Food and Drug Administration (USFDA) has issued Form 483s with 4 observations at the conclusion of the inspection at the Biocon Biologics Limited’s Biocon Campus (Site 1) facility. An FDA Form 483 is issued to firm management at the conclusion of an inspection when an investigator(s) has observed any conditions […]